You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美股異動|和黃醫藥盤前升超1% 完成HMPL-453(fanregratinib)用於治療肝內膽管癌的中國II期註冊研究的患者入組
格隆匯 03-13 17:16
和黃醫藥(HCM.US)盤前升1.36%,報15.7美元。和黃醫藥近日公吿,HMPL-453(fanregratinib)用於治療伴有成纖維細胞生長因子受體(FGFR)2融合/重排的肝內膽管癌患者的II期臨牀試驗已完成患者入組。研究的首名患者於2023年3月接受首次給藥治療,和黃醫藥預計將在2025年年底左右公佈該研究的頂線結果。若取得積極結果,將支持向中國國家藥品監督管理局提交新藥上市申請。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account